4 unchanged sentences
Amended and Restated Bylaws of Atara Biotherapeutics, Inc.
−Removed: Third Amended and Restated Exclusive License Agreement, by and between Atara Biotherapeutics, Inc.
−Removed: and the Counsel of the Queensland Institute of Medical Research, dated August 26, 2020
−Removed: Third Amended and Restated Research and Development Collaboration Agreement, by and between Atara Biotherapeutics, Inc.
−Removed: and the Counsel of the Queensland Institute of Medical Research, dated August 26, 2020
−Removed: Amended and Restated 2018 Inducement Plan
−Removed: First Amendment to Lease, by and between BXP 611 Gateway Center LP and Atara Biotherapeutics, Inc., dated as of October 21, 2020
+Added: Research, Development and License Agreement, by and between Atara Biotherapeutics, Inc.
+Added: and Bayer AG, dated December 4, 2020
+Added: Lease Agreement between LA Region No.
+Added: 2, LLC and Atara Biotherapeutics, Inc.
+Added: dated March 17, 2021
+Added: First Amended and Restated Exclusive License Agreement by and between Atara Biotherapeutics, Inc.
+Added: and Memorial Sloan Kettering Cancer Center, dated March 22, 2021
Certification by Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
7 unchanged sentences
Inline XBRL Taxonomy Extension Presentation Linkbase Document.
−Removed: The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, formatted in Inline XBRL.
−Removed: Portions of this exhibit have been omitted as being both (i) not material and (ii) would likely cause competitive harm if publicly disclosed.
−Removed: Indicates management contract or compensatory plan or arrangement.
+Added: The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, formatted in Inline XBRL.
+Added: Portions of this exhibit have been omitted as being both (i) not material and (ii) the type of information that the registrant treats as private or confidential.
+Added: Previously filed with Annual Report on Form 10-K on March 1, 2021;
+Added: refiled here with corrected formatting.
The certifications attached as Exhibit 32.1 accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C.
3 unchanged sentences
ATARA BIOTHERAPEUTICS, INC.
−Removed: November 9, 2020
/s/ Pascal Touchon
9 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.